Loading...

Prescient Therapeutics

DB:PTU
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PTU
DB
A$12M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
  • Prescient Therapeutics has significant price volatility in the past 3 months.
PTU Share Price and Events
7 Day Returns
-4%
DB:PTU
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-61.3%
DB:PTU
-9.2%
DE Biotechs
-6.7%
DE Market
PTU Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Prescient Therapeutics (PTU) -4% -20% -40% -61.3% -70.4% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • PTU underperformed the Biotechs industry which returned -9.2% over the past year.
  • PTU underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
PTU
Industry
5yr Volatility vs Market

Value

 Is Prescient Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Prescient Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.024.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Prescient Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Prescient Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PTU PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.01
ASX:PTX Share Price ** ASX (2019-04-18) in AUD A$0.05
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Prescient Therapeutics.

DB:PTU PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:PTX Share Price ÷ EPS (both in AUD)

= 0.05 ÷ -0.01

-3.34x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prescient Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Prescient Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Prescient Therapeutics's expected growth come at a high price?
Raw Data
DB:PTU PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.34x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-14.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Prescient Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Prescient Therapeutics's assets?
Raw Data
DB:PTU PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.04
ASX:PTX Share Price * ASX (2019-04-18) in AUD A$0.05
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:PTU PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:PTX Share Price ÷ Book Value per Share (both in AUD)

= 0.05 ÷ 0.04

1.25x

* Primary Listing of Prescient Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prescient Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Prescient Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Prescient Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Prescient Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-14.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Prescient Therapeutics expected to grow at an attractive rate?
  • Prescient Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Prescient Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • Prescient Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PTU Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PTU Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -14.6%
DB:PTU Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 88.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PTU Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PTU Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 45 3 1
2022-06-30 2 -26 1
2021-06-30 0 -11 1
2020-06-30 0 -6 1
2019-06-30 0 -4 1
DB:PTU Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -3 -3
2018-09-30 1 -2 -3
2018-06-30 1 -2 -3
2018-03-31 1 -3 -3
2017-12-31 1 -3 -3
2017-09-30 1 -3 -3
2017-06-30 1 -3 -3
2017-03-31 1 -3 -2
2016-12-31 1 -2 -2
2016-09-30 1 -2 -2
2016-06-30 1 -2 -2
2016-03-31 1 -2 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Prescient Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Prescient Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PTU Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Prescient Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PTU Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 0.01 0.01 0.01 1.00
2022-06-30 -0.06 -0.06 -0.06 1.00
2021-06-30 -0.03 -0.03 -0.03 1.00
2020-06-30 -0.02 -0.02 -0.02 1.00
2019-06-30 -0.01 -0.01 -0.01 1.00
DB:PTU Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.02
2016-06-30 -0.02
2016-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Prescient Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Prescient Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Prescient Therapeutics has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Prescient Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Prescient Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Prescient Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Prescient Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Prescient Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Prescient Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Prescient Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PTU Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.36 -2.99 1.66 2.70
2018-09-30 1.21 -2.78 1.60 2.38
2018-06-30 1.06 -2.57 1.55 2.06
2018-03-31 1.09 -2.65 1.42 2.27
2017-12-31 1.12 -2.72 1.28 2.48
2017-09-30 1.17 -2.65 1.31 2.46
2017-06-30 1.22 -2.57 1.33 2.43
2017-03-31 1.04 -2.36 1.55 1.82
2016-12-31 0.85 -2.16 1.77 1.21
2016-09-30 0.93 -1.95 1.86 1.00
2016-06-30 1.00 -1.75 1.95 0.80
2016-03-31 0.97 -1.72 1.78 0.91
2015-12-31 0.93 -1.69 1.61 1.02
2015-09-30 0.59 -1.91 1.48 1.01
2015-06-30 0.25 -2.13 1.34 0.99
2015-03-31 0.15 -1.89 1.29 0.69
2014-12-31 0.04 -1.65 1.24 0.40
2014-09-30 0.02 -1.71 1.28 0.20
2014-06-30 0.01 -1.77 1.32
2014-03-31 0.00 -1.48 1.03 0.00
2013-12-31 0.00 -1.19 0.74 0.00
2013-09-30 0.00 0.30 0.59 0.00
2013-06-30 1.79 0.43 0.00
2013-03-31 0.07 1.40 0.71 0.07
2012-12-31 0.13 1.01 0.99 0.13
2012-09-30 0.13 -0.44 1.13 0.29
2012-06-30 0.14 -1.89 1.27 0.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Prescient Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Prescient Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Prescient Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Prescient Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Prescient Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Prescient Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Prescient Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Prescient Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Prescient Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Prescient Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Prescient Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Prescient Therapeutics Company Filings, last reported 3 months ago.

DB:PTU Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 7.98 0.00 3.33
2018-09-30 7.98 0.00 3.33
2018-06-30 9.44 0.06 5.51
2018-03-31 9.44 0.06 5.51
2017-12-31 10.67 0.00 6.01
2017-09-30 10.67 0.00 6.01
2017-06-30 11.78 0.00 7.67
2017-03-31 11.78 0.00 7.67
2016-12-31 13.24 0.00 9.45
2016-09-30 13.24 0.00 9.45
2016-06-30 13.01 0.00 9.75
2016-03-31 13.01 0.00 9.75
2015-12-31 5.58 0.00 1.93
2015-09-30 5.58 0.00 1.93
2015-06-30 4.45 0.00 1.04
2015-03-31 4.45 0.00 1.04
2014-12-31 5.21 0.00 2.33
2014-09-30 5.21 0.00 2.33
2014-06-30 5.03 0.00 3.81
2014-03-31 5.03 0.00 3.81
2013-12-31 1.59 0.00 1.51
2013-09-30 1.59 0.00 1.51
2013-06-30 0.00 0.00
2013-03-31 0.00 0.00
2012-12-31 0.00 0.00
2012-09-30 0.00 0.00
2012-06-30 -1.79 1.10 0.03
  • Prescient Therapeutics has no debt.
  • Prescient Therapeutics had no debt 5 years ago.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Prescient Therapeutics has sufficient cash runway for 1.3 years based on current free cash flow.
  • Prescient Therapeutics has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 11.7% each year.
X
Financial health checks
We assess Prescient Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Prescient Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Prescient Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Prescient Therapeutics dividends.
If you bought €2,000 of Prescient Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Prescient Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Prescient Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PTU Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PTU Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2019-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Prescient Therapeutics has not reported any payouts.
  • Unable to verify if Prescient Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Prescient Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Prescient Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Prescient Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Prescient Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Prescient Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Prescient Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yatomi-Clarke Lee
COMPENSATION A$479,480
TENURE AS CEO 3.2 years
CEO Bio

Mr. Yatomi-Clarke Steven Lee has been Chief Executive Officer and Managing Director of Prescient Therapeutics Limited since February 15, 2016. Mr. Lee has been Director of Prescient Therapeutics Limited since November 28, 2014. He is one of Australia's most experienced biotech capital markets operatives with a successful history of financing many private and public biotech companies over the past decade. Mr. Lee serves as Director of Corporate Finance at Patersons Securities, one of Australia's oldest and largest full service stockbroking firms. He has over 15 years' experience in investment banking across a range of sectors but specialises in healthcare and biotechnology, where he has consistently been one of the most prolific bankers, involved in primary and secondary offerings, corporate advisory and mergers and acquisitions assignments for pharmaceutical and medical device companies. Mr. Lee is also a collaborator on clinical trials conducted in Australia and the US in the field of cancer immunotherapy. Mr. Lee holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology and a Bachelor of Commerce majoring in economics.

CEO Compensation
  • Yatomi-Clarke's compensation has been consistent with company performance over the past year.
  • Yatomi-Clarke's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Prescient Therapeutics management team in years:

4
Average Tenure
  • The tenure for the Prescient Therapeutics management team is about average.
Management Team

Yatomi-Clarke Lee

TITLE
MD, CEO & Director
COMPENSATION
A$479K
TENURE
3.2 yrs

Said Sebti

TITLE
Chief Scientific Officer
COMPENSATION
A$166K
TENURE
3.9 yrs

Terrence Chew

TITLE
Chief Medical Officer
COMPENSATION
A$182K
AGE
71
TENURE
4 yrs

Melanie Leydin

TITLE
Company Secretary
COMPENSATION
A$102K
AGE
45
TENURE
4.2 yrs

Claudia Gregorio-King

TITLE
Vice President of Operations
Board of Directors Tenure

Average tenure of the Prescient Therapeutics board of directors in years:

4.4
Average Tenure
  • The tenure for the Prescient Therapeutics board of directors is about average.
Board of Directors

Steve Engle

TITLE
Non-Executive Chairman
COMPENSATION
A$77K
AGE
63
TENURE
4.4 yrs

Yatomi-Clarke Lee

TITLE
MD, CEO & Director
COMPENSATION
A$479K
TENURE
4.4 yrs

Rodney Sinclair

TITLE
Chairman of Clinical Advisory Board
TENURE
7.8 yrs

James Campbell

TITLE
Non-Executive Director
COMPENSATION
A$51K
TENURE
4.4 yrs

Reinhard Dummer

TITLE
Member of Clinical Advisory Board
TENURE
7.8 yrs

Paul Edward Hopper

TITLE
Non-Executive Director
COMPENSATION
A$50K
AGE
62
TENURE
4.3 yrs

Joshua Douglas

TITLE
Member of Scientific Advisory Board
TENURE
4.6 yrs

Farhad Ravandi

TITLE
Member of Scientific Advisory Board
TENURE
3.4 yrs

Jeffrey Lancet

TITLE
Member of Scientific Advisory Board
TENURE
3.4 yrs

Thomas Prebet

TITLE
Member of Scientific Advisory Board
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Prescient Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
09. Apr 19 Buy Chris Retzos Individual 28. Jun 17 28. Mar 19 4,211,696 €0.04 €165,427
09. Apr 19 Sell Chris Retzos Individual 10. Apr 18 28. Nov 18 -2,475,000 €0.09 €-215,962
09. Apr 19 Buy Chris Retzos Individual 10. Apr 18 12. Mar 19 2,286,989 €0.09 €125,571
03. Apr 19 Sell Regal Funds Management Pty Limited Company 11. Dec 18 14. Mar 19 -1,890,128 €0.05 €-70,763
26. Mar 19 Buy James Campbell Individual 26. Mar 19 26. Mar 19 178,125 €0.04 €6,306
12. Dec 18 Sell Regal Funds Management Pty Limited Company 13. Aug 18 10. Dec 18 -2,321,532 €0.06 €-130,960
15. Aug 18 Sell Regal Funds Management Pty Limited Company 17. May 17 10. Aug 18 -14,933,331 €0.07 €-1,073,366
15. Aug 18 Buy Regal Funds Management Pty Limited Company 29. Mar 18 04. Jun 18 13,000,000 €0.07 €928,456
X
Management checks
We assess Prescient Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Prescient Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company’s lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.

Details
Name: Prescient Therapeutics Limited
PTU
Exchange: DB
Founded:
A$7,388,904
247,196,904
Website: http://www.ptxtherapeutics.com
Address: Prescient Therapeutics Limited
100 Albert Road,
Level 4,
South Melbourne,
Victoria, 3205,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX PTX Ordinary Shares Australian Securities Exchange AU AUD 02. Jan 1992
DB PTU Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
CHIA PTX Ordinary Shares Chi-X Australia AU AUD 02. Jan 1992
ASX PTXNB Npv Dfd 30/04/19(ex-Rights) Australian Securities Exchange AU AUD 27. Mar 2019
CHIA RAN NPV Chi-X Australia AU AUD 18. Apr 2019
Number of employees
Current staff
Staff numbers
0
Prescient Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:09
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/18
Last earnings filing: 2019/02/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.